News
NXTS
4.900
-5.22%
-0.270
Nexentis Expands Credit Facility Under Amended Financing Agreement
TipRanks · 20h ago
Nexentis amends L.I.A. Pure Capital facility, raising credit line to EUR 10 million
PUBT · 20h ago
Weekly Report: what happened at NXTS last week (0518-0522)?
Weekly Report · 3d ago
Nexentis Technologies says MitoCareX Bio achieves drug discovery milestone
TipRanks · 05/18 13:36
Nexentis Subsidiary MitoCareX Hits First Drug‑Discovery Milestone With Optimized Molecule
Benzinga · 05/18 13:33
Nexentis unit MitoCareX Bio generates optimized hit molecule for cancer, inflammation program
PUBT · 05/18 13:30
NEXENTIS ANNOUNCES MITOCAREX BIO ACHIEVES KEY R&D MILESTONE, GENERATING A SUBSTANTIALLY IMPROVED HIT MOLECULE ON THE PATH TO PRE-CLINICAL DEVELOPMENT
Reuters · 05/18 13:30
Weekly Report: what happened at NXTS last week (0511-0515)?
Weekly Report · 05/18 09:41
Nexentis unit MitoCareX Bio generates optimized hit molecule in MITOLINE drug program
PUBT · 05/13 11:13
Nexentis Technologies Announces Optimization of Hit Molecule at MitoCareX Bio Representing Key Drug Discovery Milestone
Barchart · 05/13 06:07
Weekly Report: what happened at NXTS last week (0504-0508)?
Weekly Report · 05/11 09:39
Nexentis Technologies Inc trading halted, volatility trading pause
TipRanks · 05/08 14:05
Nexentis Technologies Inc trading resumes
TipRanks · 05/08 13:54
Nexentis Technologies announces Mitoline U.S. trademark registration approval
TipRanks · 05/05 13:20
Nexentis Technologies' Subsidiary Receives U.S. Patent And Trademark Office Official Trademark Registration For Its MITOLINE Algorithm Platform
Benzinga · 05/05 11:49
Nexentis wins USPTO trademark registration for MitoCareX MITOLINE platform
PUBT · 05/05 11:34
Nexentis Technologies Announces U.S. Trademark Registration Approval for MitoCareX’s Algorithm Platform MITOLINE™
Barchart · 05/05 06:32
Weekly Report: what happened at NXTS last week (0427-0501)?
Weekly Report · 05/04 09:38
Nexentis Shareholders Approve Reverse Split and Financing Flexibility
TipRanks · 04/30 22:08
Nexentis Technologies holds special shareholder meeting; reverse split amendment approved
PUBT · 04/30 21:22
More
Webull provides a variety of real-time NXTS stock news. You can receive the latest news about Nexentis Technologies Inc through multiple platforms. This information may help you make smarter investment decisions.
About NXTS
Nexentis Technologies Inc, formerly known as N2OFF, Inc., is an AI and data-driven computational biotech platform focused on mitochondrial biology, precision oncology and inflammatory metabolic diseases. Through its subsidiary MitoCareX Bio Ltd. The company uses a proprietary discovery engine targeting the mitochondrial SLC25 carrier family using its MITOLINE algorithm and structure guided virtual screening workflows. MITOLINE, its proprietary computational platform, is designed to allow proper homology modeling of mitochondrial membrane proteins, particularly transport proteins. It enables three-dimensional structural modeling and large-scale virtual screening, MITOLINE opens access to a novel untapped target space, allowing the Company to identify small-molecule modulators that directly disrupt cancer metabolism with the potential of minimizing systemic toxicity.